Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors

K Subramaniam; K Tymms; B Shadbolt; P Pavli

doi:10.1111/imj.12891

Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors

Intern Med J. 2015 Nov;45(11):1154-60. doi: 10.1111/imj.12891.

Authors

K Subramaniam^{1

2}, K Tymms^{3

2}, B Shadbolt^{4

2}, P Pavli^{1

2}

Affiliations

¹ Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
² Australian National University Medical School, Canberra, Australian Capital Territory, Australia.
³ Rheumatology Department, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
⁴ Centre for Advances in Epidemiology and Information Technology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.

PMID: 26337851
DOI: 10.1111/imj.12891

Abstract

Background: Musculoskeletal symptoms are the most common extra-intestinal manifestation associated with inflammatory bowel disease (IBD). Spondyloarthritis (SpA) is an umbrella term applied to a group of rheumatic diseases with some features in common and others distinct from other inflammatory arthritides.

Aim: To determine self-reported prevalence of SpA associated musculoskeletal manifestations in an IBD cohort on tumour necrosis factor (TNF) inhibitors using a questionnaire incorporating Assessment of SpondyloArthritis International Society (ASAS) criteria.

Methods: Consecutive IBD patients on TNF inhibitors attending a single IBD centre (May-September 2011) were asked to complete a SpA questionnaire. Data collected included SpA and IBD variables, demographics, concurrent medications, co-morbidities and autoimmune serology.

Results: The 140-patient cohort included 96 suffering from Crohn disease and 44 from ulcerative colitis. The mean age of disease onset was 29.3 years and 45% were men. Concurrent or past history of inflammatory back pain was reported by 29% subjects. Using the imaging and clinical arms of the ASAS criteria, 30% and 14% subjects respectively had axial SpA. Arthritis was reported by 34%, enthesitis 17%, dactylitis 4%, uveitis 6%, psoriasis 6% and a family history of SpA in 39%. Peripheral SpA was present in 41% by the ASAS criteria. There were no differences in these frequencies between Crohn disease and ulcerative colitis. A positive antinuclear antibodies (>1:80) was found in 19% before commencement of TNF inhibitor therapy and increased to 78% on therapy. Clinical drug-induced lupus erythematosus was uncommon (4%) and was characterised by new clinical signs and symptoms, including arthralgia, rash with elevated dsDNA titres and positive antinuclear antibodies.

Conclusions: Inflammatory bowel disease patients on TNF inhibitors frequently reported musculoskeletal manifestations. Increased recognition of SpA occurred with use of an SpA self-reported questionnaire in IBD patients: this could alter management and improve patient outcomes. Clinical drug-induced lupus erythematosus was uncommon.

Keywords: clinical drug-induced lupus erythematosus; inflammatory bowel disease; spondyloarthritis; tumour necrosis factor inhibitors.

MeSH terms

Adolescent
Adult
Cohort Studies
Female
Humans
Inflammatory Bowel Diseases / diagnosis
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / epidemiology*
Infliximab / pharmacology
Infliximab / therapeutic use
Male
Middle Aged
Self Report
Spondylarthropathies / diagnosis
Spondylarthropathies / drug therapy*
Spondylarthropathies / epidemiology*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Young Adult

Substances

Tumor Necrosis Factor-alpha
Infliximab